Tissue and circulating proprotein convertase subtilisin/Kexin type 9 (PCSK9) as promising prognostic biomarkers for curative-intent colorectal liver metastases resection: A case-control study | Synapse
March 3, 2026Open Access
Tissue and circulating proprotein convertase subtilisin/Kexin type 9 (PCSK9) as promising prognostic biomarkers for curative-intent colorectal liver metastases resection: A case-control study
Puntos clave
Tissue and plasma pcsk9 levels predict outcomes after curative resection of colorectal liver metastases.
The study shows a promising link between pcsk9 expression and improved prognostic indicators in treatment.
Case-control methodology underscores the significance of biomarkers like pcsk9 in surgical decision-making.
Findings call for further validation of pcsk9 as a reliable prognostic tool in clinical practice.
Resumen
Our study indicates that both tissue and plasma PCSK9 expressions hold promise as prognostic biomarkers for curative-intent resection of CRLM.